Table 4 Baseline predictors of unacceptable pain and low inflammation—6 months and 1, 2 and 5 years after diagnosis

Female sex

1.15 (0.55–2.41)

0.83 (0.40–1.74)

2.94 (1.17–7.41)

1.87 (0.80–4.40)

RF seropositivity

0.72 (0.37–1.39)

0.72 (0.36–1.44)

0.81 (0.41–1.63)

0.54 (0.26–1.09)

Anti-CCP seropositivity

0.79 (0.39–1.60)

0.94 (0.45–1.94)

0.62 (0.29–1.31)

0.50 (0.22–0.98)

Erosion

0.11 (0.01–0.81)

0.55 (0.18–1.66)

0.24 (0.56–1.07)

0.62 (0.22–1.72)

Age

0.79 (0.58–1.10)

0.62 (0.45–0.86)

0.61 (0.44–0.85)

0.97 (0.68–1.38)

Symptom duration

1.21 (0.86–1.69)

1.37 (0.96–1.96)

0.98 (0.69–1.38)

1.19 (0.83–1.71)

Body mass index

1.28 (0.89–1.86)

0.92 (0.61–1.38)

0.95 (0.64–1.45)

0.98 (0.63–1.52)

Current smoking

0.49 (0.20–1.22)

1.07 (0.46–2.53)

0.42 (0.15–1.20)

0.77 (0.31–1.94)

Grip force

0.97 (0.68–1.37)

0.88 (0.61–1.29)

0.82 (0.56–1.21)

0.88 (0.61–1.28)

VAS pain

1.28 (0.92–1.78)

1.42 (1.00–2.01)

1.28 (0.91–1.80)

1.34 (0.94–1.92)

DAS28

1.00 (0.72–1.40)

0.96 (0.68–1.34)

0.98 (0.70–1.37)

1.00 (0.70–1.42)

SJC28

0.88 (0.63–1.24)

0.80 (0.55–1.14)

0.89 (0.63–1.25)

0.70 (0.47–1.03)

TJC28

1.23 (0.90–1.67)

1.18 (0.85–1.63)

1.14 (0.83–1.57)

1.04 (0.72–1.50)

HAQ

0.99 (0.71–1.38)

1.06 (0.76–1.49)

1.13 (0.81–1.57)

1.01 (0.72–1.43)

CRP < 9 mg/l

1.00 (reference)

1.00 (reference)

1.00 (reference)

1.00 (reference)

CRP 9–27.4 mg/l

0.50 (0.23–1.13)

0.65 (0.30–1.43)

0.66 (0.29–1.49)

1.37 (0.63–3.0)

CRP 27.5–174 mg/l

0.25 (0.09–0.68)

0.05 (0.01–0.40)

0.33 (0.12–0.92)

0.41 (0.14–1.18)

ESR (mm/h)

0.72 (0.49–1.05)

0.59 (0.38–0.93)

0.66 (0.44–1.01)

0.74 (0.50–1.11)

VAS PGA

1.14 (0.82–1.59)

1.12 (0.80–1.58)

1.24 (0.88–1.74)

1.39 (0.98–2.00)